The mechanism of action study revealed that ChA targets filamentous actin in CLL cells, thereby inducing cell cycle arrest and inhibiting cell migration, indicating that this compound is a potential CLL drug (Knudsen et al., 2014). Here, TCFL5 is linked to B-cell chronic lymphocytic leukemia.